Abstract: An encapsulated composition for converting ethanol to acetaldehyde and subsequently converting the acetaldehyde to acetate. The composition includes alcohol dehydrogenase and aldehyde dehydrogenase in a molar ratio of approximately 1:3 to approximately 1:51. The composition is encapsulated by a polysaccharide-whey-casein encapsulant such that the encapsulated composition has a controlled release property in the small intestine. The composition reduces symptoms caused by over-consumption of alcohol.

Abstract: An encapsulated composition for converting ethanol to acetaldehyde and subsequently converting the acetaldehyde to acetate. The composition includes alcohol dehydrogenase and aldehyde dehydrogenase in a molar ratio of approximately 1:3 to approximately 1:51. The composition is encapsulated by a polysaccharide-whey-casein encapsulant such that the encapsulated composition has a controlled release property in the small intestine. The composition reduces symptoms caused by over-consumption of alcohol.

Abstract: A composition includes two exogenous enzymes from animals for consumption by human beings to prevent, treat and/or alleviate veisalgia and/or symptoms associated therewith arising from or caused by consumption or spontaneous production of alcohol through a dual-enzyme based breakdown of the alcohol, wherein a first enzyme of the two exogenous enzymes is capable of converting alcohol into a first metabolite while a second enzyme thereof is capable of converting the first metabolite into a second metabolite which is excretable to systemic circulation after an oxidation reaction of the alcohol in the presence of the two exogenous enzymes and NAD+/NADH, and wherein the first enzyme to the second enzyme is in a molar ratio of 1:3-51 in the composition in order to avoid an elevation in the level of the first metabolite in the human being.

Abstract: The present invention relates to the production of the receptor binding domain (RBD) of the Spike glycoprotein 1 of the SARS-CoV-2 in mammalian cell expression systems, and the successive method of purification thereof. A recombinant plasmid containing the coding sequence of said RBD is produced and transfected in said mammalian cells, for example, Expi293. A high level of the protein is secreted in the medium and subsequently purified using the N-terminal tag, that can be removed by a specific protease. The present invention also includes a recombinant expression vector carrying the RBD gene, the successive methods for protein purification, the strategy for establishing a stable cell line producing the RBD, methods of use of the recombinant protein in formulating a pharmaceutical composition, including but not limited to, vaccines for preventing SARS-CoV-2 induced diseases.

Abstract: A composition includes two exogenous enzymes from animals for consumption by human beings to prevent, treat and/or alleviate veisalgia and/or symptoms associated therewith arising from or caused by consumption or spontaneous production of alcohol through a dual-enzyme based breakdown of the alcohol, wherein a first enzyme of the two exogenous enzymes is capable of converting alcohol into a first metabolite while a second enzyme thereof is capable of converting the first metabolite into a second metabolite which is excretable to systemic circulation after an oxidation reaction of the alcohol in the presence of the two exogenous enzymes and NAD+/NADH, and wherein the first enzyme to the second enzyme is in a molar ratio of 1:3-51 in the composition in order to avoid an elevation in the level of the first metabolite in the human being.

Abstract: The present invention relates to the production of the receptor binding domain (RBD) of the Spike glycoprotein 1 of the SARS-CoV-2 in mammalian cell expression systems, and the successive method of purification thereof. A recombinant plasmid containing the coding sequence of said RBD is produced and transfected in said mammalian cells, for example, Expi293. A high level of the protein is secreted in the medium and subsequently purified using the N-terminal tag, that can be removed by a specific protease. The present invention also includes a recombinant expression vector carrying the RBD gene, the successive methods for protein purification, the strategy for establishing a stable cell line producing the RBD, methods of use of the recombinant protein in formulating a pharmaceutical composition, including but not limited to, vaccines for preventing SARS-CoV-2 induced diseases.

Abstract: The present invention relates to the production of the receptor binding domain (RBD) of the Spike glycoprotein 1 of the SARS-CoV-2 in mammalian cell expression systems, and the successive method of purification thereof. A recombinant plasmid containing the coding sequence of said RBD is produced and transfected in said mammalian cells, for example, Expi293. A high level of the protein is secreted in the medium and subsequently purified using the N-terminal tag, that can be removed by a specific protease. The present invention also includes a recombinant expression vector carrying the RBD gene, the successive methods for protein purification, the strategy for establishing a stable cell line producing the RBD, methods of use of the recombinant protein in formulating a pharmaceutical composition, including but not limited to, vaccines for preventing SARS-CoV-2 induced diseases.

Abstract: A composition includes two exogenous enzymes from animals for consumption by human beings to prevent, treat and/or alleviate veisalgia and/or symptoms associated therewith arising from or caused by consumption or spontaneous production of alcohol through a dual-enzyme based breakdown of the alcohol, wherein a first enzyme of the two exogenous enzymes is capable of converting alcohol into a first metabolite while a second enzyme thereof is capable of converting the first metabolite into a second metabolite which is excretable to systemic circulation after an oxidation reaction of the alcohol in the presence of the two exogenous enzymes and NAD+/NADH, and wherein the first enzyme to the second enzyme is in a molar ratio of 1:3-51 in the composition in order to avoid an elevation in the level of the first metabolite in the human being.

Abstract: A composition includes two exogenous enzymes from animals for consumption by human beings to prevent, treat and/or alleviate veisalgia and/or symptoms associated therewith arising from or caused by consumption or spontaneous production of alcohol through a dual-enzyme based breakdown of the alcohol, wherein a first enzyme of the two exogenous enzymes is capable of converting alcohol into a first metabolite while a second enzyme thereof is capable of converting the first metabolite into a second metabolite which is excretable to systemic circulation after an oxidation reaction of the alcohol in the presence of the two exogenous enzymes and NAD+/NADH, and wherein the first enzyme to the second enzyme is in a molar ratio of 1:3-51 in the composition in order to avoid an elevation in the level of the first metabolite in the human being.

Abstract: A composition including two exogenous enzymes from animals for consumption by human being before and/or after consuming alcohol to prevent, treat and/or alleviate veisalgia and/or symptoms associated therewith arising from or caused by excessive consumption of alcohol through a dual-enzyme based breakdown of the excess alcohol is provided, wherein a first enzyme of the two exogenous enzymes is capable of converting alcohol into a first metabolite while a second enzyme thereof is capable of converting the first metabolite into a second metabolite which is excretable to systemic circulation after an oxidation reaction of the alcohol in the presence of the two exogenous enzymes and NAD+/NADH; the first enzyme to the second enzyme is in a molar ratio that maintains a ratio between the first and second metabolites in the human being so as to avoid local elevation of the first metabolite in the human being after consumption of excess alcohol.

Abstract: Cells within liver tumor mass comprise a unique set of proteins/tumor antigens when compared to the normal liver tissues epithelial cells juxtaposed to the tumor. The presence of tumor antigens couples the production of auto-antibodies against these tumor antigens. The present invention relates to the identification and elucidation of a protein set that can act as a novel marker set for liver cancer diagnosis and prognosis. Specifically, it relates to a kit that enables diagnostic and prognostic measurement of auto-antibodies in serum of liver cancer patients. The present invention provides a non-invasive, specific, sensitive, and cost effective detection and quantification method by evaluating a set of validated liver cancer proteins/tumor antigens, which includes Bmi-1, VCC1, SUMO-4, RhoA, TXN, ET-1, UBE2C, HDGF2, FGF21, LECT2, SOD1, STMN4, Midkine, IL-17A, IL26, or DCP to complement the conventional diagnostic methods.

Abstract: Cells within liver tumour mass comprise a unique set of proteins/tumour antigens when compared to the normal liver tissues epithelial cells juxtaposed to the tumour. The presence of tumour antigens couples the production of auto-antibodies against these tumour antigens. The present invention relates to the identification and elucidation of a protein set that can act as a novel marker set for liver cancer diagnosis and prognosis. Specifically, it relates to a kit that enables diagnostic and prognostic measurement of auto-antibodies in serum of liver cancer patients. The present invention provides a non-invasive, specific, sensitive, and cost effective detection and quantification method by evaluating a set of validated liver cancer proteins/tumour antigens, which includes Bmi-1, VCC1, SUMO-4, RhoA, TXN, ET-1, UBE2C, HDGF2, FGF21, LECT2, SOD1, STMN4, Midkine, IL-17A or IL26, to complement the conventional diagnostic methods.

Abstract: The present invention provides a method for inhibiting chondroitinase activity in a substrate by introducing a non-substrate glycosaminoglycan (GAG) to the substrate containing the chondroitinase. The non-substrate GAG is undegradable by chondroitinase. The GAG may be administered as a single dose or in multiple doses. The chondroitinase may be Chondroitinase B, Chondroitinase C, Chondroitinase AC, or Chondroitinase ABC. The substrate may be one or more of dermatan sulfate, hyaluronic acid, chondroitin sulfate, or derivatives thereof. The non-substrate GAG may be from naturally unbranched homo-polysaccharide, unnaturally branched GAG, or a hybrid GAG molecule fused of two or three GAG chains, being produced by chemical synthesis or enzymatic reaction. The non-substrate GAG may be heparin, heparan sulfate, and keratan sulfate. The non-substrate GAG may bind to the active residue of the chondroitinase when being introduced to the substrate such that the chondroitinase is no longer enzymatically active.

Abstract: The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent/therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent to give a synergistic effect on cancer treatment, inhibiting metastasis and/or reducing recurrence. The presently claimed hemoglobin-based 5FU-two-dye conjugate and/or hemoglobin-based 5FU-one-dye conjugate can also be used in live-cell imaging and diagnostic imaging.

Abstract: The present invention provides a method for purifying Chondroitinase ABC (ChABC). The present method includes using a heparin-immobilized affinity chromatography column, and through chromatography method obtaining a purified ChABC from a matrix containing the ChABC. The present method is capable of obtaining ChABC in high purity with the advantages of simplicity in preparation and high yield.

Abstract: The present invention provides a method for purifying Chondroitinase ABC (ChABC). The present method includes using a heparin-immobilized affinity chromatography column, and through chromatography method obtaining a purified ChABC from a matrix containing said ChABC. The present method is capable of obtaining ChABC in high purity with the advantages of simplicity in preparation and high yield.

Abstract: The present invention provides an enteric-coated hemoglobin multiparticulate comprising a core, a hemoglobin formulation coating, an inner or sub-coating, and an enteric coating. The present invention also provides a method of preparing said enteric-coated hemoglobin multiparticulate. The present invention further provides a method for treating various diseases caused by oxygen deficiency comprising administering to a subject said enteric-coated hemoglobin multiparticulate in order to orally deliver the encapsulated hemoglobin-based oxygen carriers to a specific target of said subject in a controlled release manner.

Abstract: The present invention provides a method for purifying Chondroitinase ABC (ChABC). The present method includes using a heparin-immobilized affinity chromatography column, and through chromatography method obtaining a purified ChABC from a matrix containing said ChABC. The present method is capable of obtaining ChABC in high purity with the advantages of simplicity in preparation and high yield.

Abstract: The present invention provides a pharmaceutical composition containing albumin-binding arginine deiminase fusion protein (AAD) for treating cancer or other arginine-dependent diseases. The AAD fission protein can be purified from both soluble and insoluble fractions of crude proteins, it binds to human serum albumin (HSA) and has its high activity with longer half life for efficient depletion of arginine in cancer cells. The specific activities of wild-type ADI and AAD in the present invention are 8.4 and 9.2 U/mg (at physiological pH 7.4), respectively. The AAD used in the present invention can be used in the treatment of various cancers (e.g. pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer & brain cancer) and curing arginine-dependent diseases.

Abstract: The present invention provides a pharmaceutical composition containing albumin-binding arginine deiminase (AAD) fusion protein for treating cancer or other arginine-dependent diseases. The AAD fusion protein can be purified from both soluble and insoluble fractions of crude proteins, binds to human serum albumin (HSA) or animal serum albumin and has its high activity with longer half life for efficient depletion of arginine in cancer cells. The specific activities of wild-type ADI and AAD fusion protein in the present invention are about 20 and about 19 U/mg (at physiological pH 7.4), respectively. The composition can be used alone or in combination with at least one chemotherapeutic agent to give a synergistic effect on cancer treatment and/or inhibiting metastasis. The AAD fusion protein can also be used as a component for detection and quantitative analysis of arginine in a testing kit for various samples including blood, food and analytical samples.